BioDelivery Sciences International Inc - Strategic SWOT Analysis Review

BioDelivery Sciences International Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description - A detailed description of the company’s operations and business divisions.
• Corporate strategy - The publisher's summarization of the company’s business strategy.
• SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history - Progression of key events associated with the company.
• Major products and services - A list of major products, services and brands of the company.
• Key competitors - A list of key competitors to the company.
• Key employees - A list of the key executives of the company.
• Executive biographies - A brief summary of the executives’ employment history.
• Key operational heads - A list of personnel heading key departments/functions.
• Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

BioDelivery Sciences International Inc (BDSI) is a specialty pharmaceutical company that develops and commercializes products in the areas of addiction medicine and pain management. The company’s marketed products include fentanyl buccal soluble solution for breakthrough cancer pain; buprenorphine buccal film for chronic pain and buprenorphine/naloxone buccal film for opioid dependence. Its pipeline encompasses indications targeted at the treatment of chronic pain and opioid dependence. BDSI employs its proprietary BioErodible MucoAdhesive (BEMA) technology which comprises small, bioerodible polymer film used to facilitate rapid delivery of a drug across the mucous membranes for time sensitive conditions. BDSI is headquartered in Raleigh, North Carolina, the US.

BioDelivery Sciences International Inc Key Recent Developments

• Feb 15, 2022: Collegium Pharmaceutical to purchase BioDelivery Sciences for $604m
• Jan 20, 2022: BioDelivery Sciences expects 2021 revenue at the high end of full year guidance
• Nov 03, 2021: BioDelivery Sciences Reports Solid Third Quarter 2021 Results
• Oct 21, 2021: BioDelivery Sciences Appoints John Golubieski as Chief Financial Officer
• Sep 30, 2021: BioDelivery Sciences International to Host ELYXYB Investor Day

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with the publisher's detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.